以生理学为基础的药理动力学建模,以评估里托纳维尔-迪戈辛相互作用,并为联合管理方案提出建议
Youjun Chen1,2, Wenxin Shao1,2, Xingwen Wang1,2
1Anhui Provincial Center for Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, 241001, Anhui, China.
利托纳维尔显著增加了狄戈辛水平,造成毒性风险. PBPK建模建议将狄戈辛剂量减少45%或将间隔翻一番,以安全地管理这种药物相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物的新陈代谢和运输
- 计算生物学 计算生物学
背景情况:
- 迪戈辛是一种心脏糖化物,由P-glycoprotein (P-gp) 运输.
- 利托纳维尔是一种已知的P-gp抑制剂.
- 利托纳维尔和狄戈辛的同时使用可以提高狄戈辛的血度,由于狄戈辛的治疗指数狭窄,可能导致毒性.
研究的目的:
- 使用生理学基础的药理动力学 (PBPK) 模型预测里托纳维尔-迪戈辛相互作用的药理动力学影响.
- 提供剂量建议,以确保利托纳维尔和迪戈辛的安全同时使用.
主要方法:
- 使用PK-Sim®开发单个PBPK模型,用于利托纳维尔和迪戈辛.
- 模拟药物相互作用 (DDI) 通过将利托纳维尔的P-gp抑制纳入迪戈辛.
- 通过比较预测和观察到的药理动力学参数和度-时间概况来验证PBPK模型.
主要成果:
- 模型模拟表明,当与利托纳维尔联合使用时,滴毒素稳定状态暴露的实质性增加:口服剂量为86.5-90.2%,静脉注射剂量为80.2-90.2%.
- 预计将狄戈辛剂量减少45%或将口服剂量间隔翻一番,可以保持与单一治疗相似的稳定状态度.
结论:
- 药物相互作用显著改变狄戈辛的血度.
- 对P-gp介导的药物相互作用的临床考虑对于安全有效的迪戈辛治疗至关重要.
- PBPK建模为预测和管理药物相互作用提供了宝贵的工具.
更多相关视频
08:28Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
11:06Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Physiological Models
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
Physiological Pharmacokinetic Models: Assumption with Protein Binding
